Cramer Favors J&J, Warns Against AMD
Locales: New Jersey, UNITED STATES

New York, NY - January 21, 2026 - In a stark contrast to the current market fervor surrounding high-growth tech stocks, CNBC's Jim Cramer today issued a strong endorsement for Johnson & Johnson (JNJ) during his 'Mad Money' segment, while simultaneously advising caution against further investment in Advanced Micro Devices (AMD). Cramer's guidance underscores a shift towards prioritizing stability and value in an increasingly volatile market.
Cramer's recommendation for Johnson & Johnson comes on the heels of the company's recent earnings report and seemingly counteracts the prevailing investor enthusiasm for faster-growing, albeit often more speculative, equities. He reiterated his conviction, stating he is "sticking with the name," highlighting the company's consistent performance and its attractive dividend yield. J&J shares reacted positively to the endorsement, climbing 1.5% to close at $166.90.
"The stock's done nothing, absolutely nothing, but sit still and pay you a dividend," Cramer remarked, emphasizing the often-overlooked appeal of reliable income generation in uncertain times. He contrasted J&J's steady performance with the frenzied chasing of "shiny objects" - a clear reference to the rapid gains witnessed by companies like AMD. The appeal of Johnson & Johnson, in Cramer's view, lies in its resilience and ability to provide consistent returns even amidst market fluctuations. J&J's longstanding status as a healthcare giant, combined with its history of innovation and stability, positions it as a safe harbor for investors seeking a more conservative approach.
The contrasting sentiment towards Advanced Micro Devices presents a compelling case for Cramer's broader investment philosophy. While acknowledging AMD's position as a "great company" - a nod to its advancements in semiconductor technology - Cramer believes the stock's recent rally has driven its valuation beyond justifiable levels. He cautioned investors against joining the momentum, warning that the stock is now "overvalued." Following Cramer's commentary, AMD shares dipped 0.5%, settling at $171.19.
The divergence in Cramer's recommendations speaks volumes about the current market landscape. The frenzy surrounding technology, particularly semiconductor manufacturers, has fueled significant gains, attracting a wave of retail and institutional investors. While acknowledging the long-term potential of these companies, Cramer's advice suggests a necessary recalibration of expectations. He advocates for a more discerning approach, prioritizing companies with strong fundamentals and sustainable growth prospects over the allure of rapid, but potentially unsustainable, gains.
Beyond the specific recommendations of J&J and AMD, Cramer's broader message was one of patience and disciplined investing. He urged investors to "focus on quality companies and ignore the noise of short-term market fluctuations." This sentiment reflects a growing concern among seasoned analysts about market exuberance and the potential for a correction. Cramer's perspective encourages investors to adopt a long-term view, prioritizing the stability and profitability of underlying businesses over the ephemeral thrill of short-term trading.
Market Context & Implications
The advice comes at a time when inflation remains a persistent concern globally, and interest rates, while expected to ease in the latter half of 2026, continue to exert a dampening effect on economic growth. In this environment, investments perceived as safe havens, like Johnson & Johnson, often attract increased demand. Conversely, companies with high growth expectations, like AMD, are more sensitive to shifts in economic sentiment and interest rate policy.
Cramer's commentary highlights a key debate within the investment community: the balance between growth and value. While growth stocks offer the potential for significant returns, they also carry higher levels of risk. Value stocks, like J&J, offer less potential for explosive growth but are generally considered more stable and less prone to dramatic swings in price. Cramer's current stance suggests a growing preference for value, reflecting a more cautious and risk-averse approach to investing.
Read the Full CNBC Article at:
[ https://www.cnbc.com/2026/01/21/cramer-says-health-care-giant-is-a-buy-warns-not-to-chase-rally-in-amd.html ]